Neptune Technologies & Bioressources-Ord  

(Public, NASDAQ:NEPT)   Watch this stock  
Find more results for NEPT
-0.03 (-1.60%)
Dec 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.83 - 1.94
52 week 1.11 - 3.61
Open 1.85
Vol / Avg. 48,666.00/110,003.00
Mkt cap 138.71M
P/E     -
Div/yield     -
EPS -0.35
Shares 73.79M
Beta 2.30
Inst. own     -
Oct 15, 2014
Q2 2015 Neptune Technologies & Bioressources Inc Earnings Call
Oct 14, 2014
Q2 2015 Neptune Technologies & Bioressources Inc Earnings Release
More events from DailyFinance »    


545 Prom du Centropolis Suite 100
+1-450-6872262 (Phone)
+1-450-6872272 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Neptune Technologies & Bioressources Inc. (Neptune) is a biotechnology company. The Company is engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids (PUFAs). The Company operates in three segments: Neptune, Acasti Pharma Inc. and Acasti Pharma Inc. Its Neptune produces and commercializes nutraceutical products. Its Acasti Pharma Inc. develops and commercializes pharmaceutical applications for cardiovascular diseases. Its NeuroBioPharm Inc. develops and commercializes pharmaceutical applications for neurological diseases. It produces omega-3 PUFAs through its patented process of extracting oils from Antartic krill, which omega-3 PUFAs are then principally sold as bulk oil to Neptune�s distributors who commercialize them under their private label primarily in the United States, European and Australian nutraceutical markets. The Company�s products include Neptune Krill Oil (NKO) and ECOKRILL Oil (EKO).

Officers and directors

Pierre Fitzgibbon Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Andre Godin Chief Financial Officer
Bio & Compensation  - Reuters
Michel Timperio Senior Vice President of Sales - Global Sales
Bio & Compensation  - Reuters
Wael Massrieh Vice President - Scientific Affairs
Bio & Compensation  - Reuters
Fotini Sampalis M.D., Ph.D. Chief Global Strategy Officer
Bio & Compensation  - Reuters
Ronald Denis Director
Bio & Compensation  - Reuters
Harlan W. Waksal M.D. Director
Age: 60
Bio & Compensation  - Reuters
Valier Boivin Independent Director
Bio & Compensation  - Reuters
Adrian Montgomery Independent Director
Bio & Compensation  - Reuters
John Moretz Independent Director
Bio & Compensation  - Reuters